[ad_1]
Photo by Agustino Marcariano (Reuters / Scanpix)
Clinical trials show that the efficacy of the Sputnik V vaccine against coronavirus, developed in Russia, is 91.8%.
According to Rao Politico, such an introduction came after a three-phase clinical trial that examined 20,000 participants in different locations in Russia. 21 days after the first vaccination, 16 cases of coronavirus were reported in the 62 placebo vaccine group.
No more serious cases of the disease have been reported among the infected person and the effectiveness of the vaccine has been studied in people over 60 years of age. The vaccine was also effective for them.
It is possible that although the Sputnik V vaccine was approved in Russia last summer and is now licensed in 15 countries, phase III clinical trials have not been conducted to determine the safety and efficacy of the vaccine. As a result, the vaccine was criticized and questioned by the scientific community.
Following the investigation, the Russian company Sputnik, which developed the vaccine, can now apply to the European Medicines Agency (EMA) for licensing in Europe.
The EEA is currently working on vaccine stocks, and European countries that have previously criticized the Russian vaccine are already talking about its use in Europe.
Rayti komentar
[ad_2]
